// App-Quantinova.ai

5508 : Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.

Researchers

Presenter

  • Juliet Elizabeth Wolford

Principal Investigators

  • Jiaru Bai

  • Lindsey E. Minion

  • Robin Keller

  • Ramez Nassef Eskander

  • John K. Chan

  • Bradley J. Monk

  • Krishnansu Sujata Tewari

Medical Centers

  • University of California, Irvine, Fullerton, CA

  • School of Management, Binghamton University, State University of New York, Binghamton, NY

  • University of California Irvine Paul Merage School of Business, Irvine, CA

  • UCSD Moores Cancer Center, La Jolla, CA

  • Palo Alto Medical Foundation, San Francisco, CA

  • University of Arizona Cancer Center at Dignity Health St. Joseph's Hospital and Medical Center, Phoenix, AZ

  • The Division of Gynecologic Oncology at the University of California, Irvine, Orange, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • BRCA mutation

Drug/Treatment

  • Pembrolizumab

  • Bevacizumab

  • Paclitaxel

  • Rucaparib

  • Niraparib

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved